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econdary bacterial infections among two cohorts of adults
n Brazil.
Methods: We created an initial decision model to eval-
ate the cost-effectiveness of PPV23 used as part of a
omprehensive pandemic plan in the United States. This
odel was adapted to reﬂect cost data from Brazil. Two
ohorts of 6 million Brazilian adults, aged 20-64, were
odeled: high-risk adults and critical workers. The model
ompares costs and disease outcomes associated with two
accination scenarios: PPV23 vaccination and no PPV23
accination. Outcomes are based on attack rates from
wo prior pandemic types: severe (1918) and moderate
1957/1968). PPV23 effectiveness was assumed to be 59%.
accine costs consisted of dose and administration costs.
osts are reported in 2008 Brazilian reals. Cost effective-
ess results are reported as incremental cost effectiveness
atios (ICER) using reals per Quality Adjusted Life Year
QALY).
Results: Under the assumption that no pandemic
nﬂuenza vaccine is available, PPV23 could prevent approx-
mately 15,000 pneumococcal disease cases in the high-risk
opulation during a severe pandemic and 9,000 cases dur-
ng a moderate pandemic. Among 6 million high-risk adults,
he ICERs comparing the PPV23 vaccination scenario ver-
us no PPV23 were estimated to be 1,700 reals per QALY
or a severe pandemic and 18,000 reals per QALY for a
oderate pandemic. Among 6 million critical workers aged
0-64, PPV23 could prevent 64,000 missed work days during
severe pandemic and 17,000 missed work days during a
oderate pandemic.
Conclusion: The cost effectiveness ratios for mass vac-
ination of high risk individuals as well as critical workers
sing PPV23 in Brazil to prevent secondary bacterial infec-
ions related to pandemic inﬂuenza fall within the range
enerally considered to be cost-effective; however, the
ost-effectiveness ratios depend on the severity of the pan-
emic.
oi:10.1016/j.ijid.2010.02.617
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Background: Sikkim is a small state of India which
ntroduced hepatitis B vaccination into its immunization
chedule. Sikkim is the ﬁrst state of India to introduce Hep-
titis vaccination in the year 2004. Hepatitis B coverage for
he state of Sikkim is approximately 10,000 children per year
nd immunization is done at 6, 10 and 14 weeks of age.
ooster dose has not been incorporated in the immunization
chedule. Since the time of introduction of immunization
o impact study has been done in the vaccinated children.
hether the children being vaccinated mount an adequate
ntibody response against the vaccine needs to be investi-
ated. An attempt was made to study the anti-HBs levels in
cross sectional study of children who received the vacci-
ation against Hepatitis B.
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Methods: 160 post vaccinated children and adolescents
ere included in the study. Only those who had completed
hree doses of the vaccination were included. Serum col-
ected was tested using a commercially available sandwich
LISA kit. The quality control criteria were fulﬁlled and the
ata was analyzed. Anti-HBs Levels below 10mIU/ml were
onsidered as non responders and levels above 10mIU/ml
ere considered as responders.
Results: 53.1% of the participants were males and 46.9%
ere females. Analysis of data revealed that 64.4% of the
opulation under study were responders and 35.6% were
on responders. Female participants who were non respon-
ers were greater than males (38.6%: 32.9%). No signiﬁcant
elation between age and response was seen.
Conclusion: The percentage of non-responders in the post
accination children was signiﬁcantly higher as compared
o most studies conducted in other countries. No study has
een done in India to see the impact of vaccination in chil-
ren. Females seem to be non responders as compared
o males contrary to some studies. Further studies need
o be conducted to investigate the cause of this anomaly.
resuming that India is on the verge of introducing uni-
ersal vaccination against HBV, preparedness to encounter
he problem of non responders to vaccination needs to be
ddressed and a strategy developed to counter it.
oi:10.1016/j.ijid.2010.02.618
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Background: Although poliomyelitis caused by wild-type
oliovirus has been almost eradicated, especially in devel-
ped countries, vaccine associated paralytic poliomyelitis
VAPP) cases still continue to occur in Latin American coun-
ries. In Argentina, where OPV routine immunization policy
s ongoing, the last wild poliovirus (WPV) case was registered
n 1984. Since then, the several polio cases reported were
APP and Vaccine Derived Poliovirus (VDPV) (ﬁrst iVDPV case
as detected in 1998).
Methods: To report a polio case caused by a VDPV in an
mmunodeﬁcient patient diagnosed with polyclonal agam-
aglobulinemia.
Results: In May 2009 a 15 month-old patient was hospi-
alized in our institution for acute ﬂaccid monoparesis in his
eft lower limb with areﬂexia, with residual paralysis 60 days
fter onset. The patient had a history of recurrent infections
sepsis meningitis and pneumonia).Vaccination calendar was
ompleted for his age (DPt/Hib-HB & OPV: 3 doses). The
hild received OPV3, 8 months before. LCR 8 cells/prot
5mg/100mL/Glu 50mg/ml with negative cultures (bac-
eria -mycobacterium, fungi). EMG showed pre-ganglionic
njury. Spine MRI showed focal intramedullary cone and
